Patent · US Active

Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

US8986709B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
INSTITUT PASTEUR DE LILLE · FR
National University of Ireland Maynooth · IE

Inventors

Camille Locht · Wannehain, FR
Bernard Mahon · Maynooth, IE
Heather Kavanagh · Dublin, IE

Key dates

Filing date	Mar 1, 2013
Grant date	Mar 24, 2015
Priority date	—
Expiry date	Mar 1, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/544
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.